12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Eluxadoline: Completed Phase III enrollment

Furiex completed enrollment in a 52-week, double-blind, placebo-controlled international Phase III trial evaluating 75 and 100 mg twice-daily oral eluxadoline. Furiex, which spun out of PPD LLC (Wilmington, N.C.) in 2010, has exclusive rights to eluxadoline from...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >